Late toxicity in long-term survivors from a phase 2 study of concurrent radiation therapy, temozolomide and valproic acid for newly diagnosed glioblastoma

Схожие документы

• A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid For Patients With Glioblastoma
  по: Krauze, Andra V., et al.
  Опубликовано: (2015)
• AT-33 A PHASE II STUDY OF CONCURRENT RADIATION THERAPY, TEMOZOLOMIDE AND THE HISTONE DEACETYLASE INHIBITOR VALPROIC ACID FOR PATIENTS WITH GLIOBLASTOMA MULTIFORME
  по: Krauze, Andra V., et al.
  Опубликовано: (2014)
• Radiosensitizers in the temozolomide era for newly diagnosed glioblastoma
  по: Mathen, Peter, et al.
  Опубликовано: (2020)
• ACTR-57. DOES THE ADDITION OF VALPROIC ACID TO CONCURRENT RADIATION THERAPY AND TEMOZOLOMIDE IMPROVE PATIENT OUTCOME? – CORRELATIVE ANALYSIS OF RTOG 0525, SEER AND A PHASE II NCI TRIAL
  по: Krauze, Andra, et al.
  Опубликовано: (2017)
• RTHP-15. INCIDENCE OF MASTOID EFFUSION IN PATIENTS RECEIVING PHOTON RADIATION THERAPY FOR GLIOBLASTOMA
  по: Rowe, Lindsay, et al.
  Опубликовано: (2017)